Silky Rajesh Punyani1, Ramhari Shankarrao Sathawane. 1. Department of Oral Medicine and Radiology, Government Dental College and Hospital, 1135-Kaushal Bhavan, Central Avenue, Gandhibagh, Nagpur, Maharashtra, 440032, India. dr.srpunyani@gmail.com
Abstract
BACKGROUND: Interleukin 8 (IL-8) is a pro-angiogenic, pro-inflammatory mediator that belongs to the family of chemokines. Due to its pro-angiogenic characteristic, it may play a vital role in tumour angiogenesis and progression. OBJECTIVES: This study was designed to estimate the levels of salivary IL-8 in oral precancer and oral squamous cell carcinoma (OSCC) patients and compare them with healthy controls. The aim was to evaluate its efficacy as a potential biomarker for these diseases. MATERIALS AND METHODS: Each group comprised 25 individuals. The salivary IL-8 levels were determined by enzyme-linked immunosorbent assay. RESULTS: The levels of salivary IL-8 were found to be significantly elevated in patients with OSCC as compared to the precancer group (p < 0.0001) and healthy controls (p < 0.0001). However, the difference in salivary IL-8 concentrations among the precancer group and controls was statistically non-significant (p = 0.738). CONCLUSIONS: Our results suggested that salivary IL-8 can be utilised as a potential biomarker for OSCC. Salivary IL-8 was found to be non-conclusive for oral premalignancy in this preliminary study. Hence, its possible role in transition from premalignancy to malignancy needs further research with larger sample sizes. CLINICAL RELEVANCE: Saliva as a diagnostic biofluid offers a number of advantages over blood-based testing. The role of IL-8 in oral cancer if validated further by future research can provide an easy diagnostic test as well as a prognostic indicator for patients undergoing treatment. Therefore, if it's role in tumourigenesis can be sufficiently assessed, it could open up new avenues to find out novel treatment modalities for oral cancer.
BACKGROUND:Interleukin 8 (IL-8) is a pro-angiogenic, pro-inflammatory mediator that belongs to the family of chemokines. Due to its pro-angiogenic characteristic, it may play a vital role in tumour angiogenesis and progression. OBJECTIVES: This study was designed to estimate the levels of salivary IL-8 in oral precancer and oral squamous cell carcinoma (OSCC) patients and compare them with healthy controls. The aim was to evaluate its efficacy as a potential biomarker for these diseases. MATERIALS AND METHODS: Each group comprised 25 individuals. The salivary IL-8 levels were determined by enzyme-linked immunosorbent assay. RESULTS: The levels of salivary IL-8 were found to be significantly elevated in patients with OSCC as compared to the precancer group (p < 0.0001) and healthy controls (p < 0.0001). However, the difference in salivary IL-8 concentrations among the precancer group and controls was statistically non-significant (p = 0.738). CONCLUSIONS: Our results suggested that salivary IL-8 can be utilised as a potential biomarker for OSCC. Salivary IL-8 was found to be non-conclusive for oral premalignancy in this preliminary study. Hence, its possible role in transition from premalignancy to malignancy needs further research with larger sample sizes. CLINICAL RELEVANCE: Saliva as a diagnostic biofluid offers a number of advantages over blood-based testing. The role of IL-8 in oral cancer if validated further by future research can provide an easy diagnostic test as well as a prognostic indicator for patients undergoing treatment. Therefore, if it's role in tumourigenesis can be sufficiently assessed, it could open up new avenues to find out novel treatment modalities for oral cancer.
Authors: C W Smith; Z Chen; G Dong; E Loukinova; M Y Pegram; L Nicholas-Figueroa; C Van Waes Journal: Clin Exp Metastasis Date: 1998-10 Impact factor: 5.150
Authors: Leticia Bagan; Guillermo T Sáez; M Carmen Tormos; Carlos Labaig-Rueda; Judith Murillo-Cortes; Jose V Bagan Journal: Clin Oral Investig Date: 2015-08-09 Impact factor: 3.573
Authors: Frederico Omar Gleber-Netto; Maha Yakob; Feng Li; Ziding Feng; Jianliang Dai; Huang-Kai Kao; Yu-Liang Chang; Kai-Ping Chang; David T W Wong Journal: Clin Cancer Res Date: 2016-02-04 Impact factor: 12.531
Authors: Elena Ferrari; Margherita E Pezzi; Diana Cassi; Thelma A Pertinhez; Alberto Spisni; Marco Meleti Journal: Int J Mol Sci Date: 2021-06-24 Impact factor: 5.923
Authors: Nilminie Rathnayake; Sigvard Akerman; Björn Klinge; Nina Lundegren; Henrik Jansson; Ylva Tryselius; Timo Sorsa; Anders Gustafsson Journal: PLoS One Date: 2013-04-24 Impact factor: 3.240